Titan Pharmaceuticals TTNP Stock
Titan Pharmaceuticals Price Chart
Titan Pharmaceuticals TTNP Financial and Trading Overview
| Titan Pharmaceuticals stock price | 6.42 USD |
| Previous Close | 0.75 USD |
| Open | 0.73 USD |
| Bid | 0 USD x 1400 |
| Ask | 0 USD x 1800 |
| Day's Range | 0.73 - 0.77 USD |
| 52 Week Range | 0.5 - 1.59 USD |
| Volume | 6.58K USD |
| Avg. Volume | 12.23K USD |
| Market Cap | 11.26M USD |
| Beta (5Y Monthly) | 1.096478 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.42 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7 USD |
TTNP Valuation Measures
| Enterprise Value | 10.3M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.8241758 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 24.324461 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 22.245 |
| Enterprise Value/EBITDA | -1.176 |
Trading Information
Titan Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.096478 |
| 52-Week Change | 31.57% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.59 USD |
| 52 Week Low | 0.5 USD |
| 50-Day Moving Average | 0.78 USD |
| 200-Day Moving Average | 0.92 USD |
TTNP Share Statistics
| Avg. Volume (3 month) | 12.23K USD |
| Avg. Daily Volume (10-Days) | 10.37K USD |
| Shares Outstanding | 15.02M |
| Float | 11.21M |
| Short Ratio | 3.41 |
| % Held by Insiders | 25.32% |
| % Held by Institutions | 9.73% |
| Shares Short | 49.12K |
| Short % of Float | 0.41% |
| Short % of Shares Outstanding | 0.33% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2028.72% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -94.035% |
| Return on Equity (ttm) | -246.79% |
Income Statement
| Revenue (ttm) | 463K USD |
| Revenue Per Share (ttm) | 0.03 USD |
| Quarterly Revenue Growth (yoy) | -49.00000000000000000000000000000000% |
| Gross Profit (ttm) | N/A |
| EBITDA | -8756000 USD |
| Net Income Avi to Common (ttm) | -9341000 USD |
| Diluted EPS (ttm) | -0.63 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.14M USD |
| Total Cash Per Share (mrq) | 0.08 USD |
| Total Debt (mrq) | 158K USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.729 |
| Book Value Per Share (mrq) | -0.021 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7118000 USD |
| Levered Free Cash Flow (ttm) | -3245625 USD |
Profile of Titan Pharmaceuticals
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 400 Oyster Point Boulevard |
| ZIP | 94080 |
| Phone | 650 244 4990 |
| Website | https://www.titanpharm.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 4 |
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Q&A For Titan Pharmaceuticals Stock
What is a current TTNP stock price?
Titan Pharmaceuticals TTNP stock price today per share is 6.42 USD.
How to purchase Titan Pharmaceuticals stock?
You can buy TTNP shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Titan Pharmaceuticals?
The stock symbol or ticker of Titan Pharmaceuticals is TTNP.
Which industry does the Titan Pharmaceuticals company belong to?
The Titan Pharmaceuticals industry is Biotechnology.
How many shares does Titan Pharmaceuticals have in circulation?
The max supply of Titan Pharmaceuticals shares is 914.23K.
What is Titan Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Titan Pharmaceuticals PE Ratio is now.
What was Titan Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Titan Pharmaceuticals EPS is -6.42 USD over the trailing 12 months.
Which sector does the Titan Pharmaceuticals company belong to?
The Titan Pharmaceuticals sector is Healthcare.
Titan Pharmaceuticals TTNP included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16920.58 USD — |
-0.58
|
6.33B USD — | 16873.97 USD — | 16989.6 USD — | — - | 6.33B USD — |
| NASDAQ Composite Total Return I XCMP | 20585.06 USD — |
-0.58
|
— — | 20528.35 USD — | 20669.02 USD — | — - | — — |
| NASDAQ Capital Market Composite RCMP | 111.05 USD — |
-1.6
|
— — | 110.9 USD — | 111.54 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 967.78 USD — |
-1.12
|
— — | 964.91 USD — | 969.79 USD — | — - | — — |
- {{ link.label }} {{link}}